All abstracts are blinded, peer-reviewed and ranked on the basis of scientific merit by experts in the category selected. The AASLD Scientific Program Committee uses these rankings to develop the scientific program of the conference. Abstracts are allocated to short oral plenary and parallel presentations (10 minute presentation plus a 5 minute Q&A period) and poster sessions based on their focus of interest. Authors who do not wish to be considered for oral presentation should check the "Poster Only" option under Step 2: Properties in the online abstract submitter (Opened April 1 and closed June 3). All abstract presenters must register for the AASLD Annual Meeting.
AASLD Abstract Review and Selection Policy
Abstracts are scored by at least four reviewers for each category and ranked according to numerical score. Reviewers are blinded to the author's names and affiliations. Reviewers with conflicts do not score pertinent abstracts. Abstracts are ranked within the category that is selected by the submitter, although if selected, abstracts may be moved into other content areas for presentation.
Abstracts are selected for oral and poster presentations based on the integration of the abstract subject into sessions within a specific topic, abstract rank, and suitability of the content for presentation. Posters of Distinction are considered to be particularly noteworthy and represent the top 10% of all accepted poster presentations.
If abstracts contain incomplete data at the time of submission, the abstract will receive a lower priority score. In such circumstances, consideration should be given to submitting the complete data as a "late-breaker" for the Annual Meeting.
Original research that was not completed until after the June 3, 2020 abstract deadline for The Liver Meeting® may be eligible for submission as a late-breaking abstract. The late-breaking abstract submission period will open in September 2020.
Novel clinical observations can provide new insight into clinical phenotypes or pathogenesis of disease. Case reports are not frequently submitted to The Liver Meeting® but authors who so choose may submit one using the same guidelines outlined below for standard abstract submission. Case reports will be scored and ranked by the same review team that scores abstract submissions for the category and descriptor selected by the submitting author.
The initial responsibility for adherence to ethical guidelines lies with the responsible investigators submitting their research findings to AASLD meetings or journals.
- For reports of research using human subjects, provide assurance that (a) informed consent in writing was obtained from each patient and (b) the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a prior approval by the appropriate institutional review committee. Refer to individual patients by number, not by initials.
- HEPATOLOGY will only accept papers for review from liver transplant centers that explicitly state that no donor organs were obtained from executed prisoners or other institutionalized persons. Papers without such explicit statements will be returned without review.
- In studies involving animal experimentation, provide assurance that all animals received humane care according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals [PDF] prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication 86-23 revised 1985).
It is the policy of the American Association for the Study of Liver Diseases (AASLD) to ensure balance, independence, objectivity, and scientific rigor in all its individually or jointly provided educational programs. All faculty/authors participating in any AASLD sponsored programs, as well as planners and committee members are expected to disclose any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing medical education program.
All abstract authors must complete their own financial disclosure statement on the abstract submission site either disclosing all financial relationships with commercial interests or indicating that none exist. Submitting authors will NOT have the ability to submit disclosures on behalf of a co-author.
Disclosures not received before the deadline stated in the abstract acceptance notice will be administratively withdrawn.
Embargo Update (as of Oct. 18, 2022)
The embargo for all regular abstracts will lift on Friday, Oct. 21, 2022, at 9 AM, ET. This does NOT apply to late-breaking abstracts.
Embargo Update (as of Oct. 14, 2022)
Presenters whose abstracts have been accepted to The Liver Meeting may now promote the titles, authors, and sessions they will be presenting in. This EXCLUDES any late-breaking abstracts. Abstracts will be made available on the AASLD website, the TLM app, and the TLMdX platform prior to the start of The Liver Meeting at a date to be determined.
All attendees, members of the media, companies, institutions, organizations, universities, investment advisors, and all other individuals, are required to abide by AASLD’s Abstract Embargo Policy governing The Liver Meeting®.
An embargo means that information contained in any abstract is confidential and may not be announced, publicized, or distributed before the embargo date and time except as permitted by this policy. However, information beyond that contained in the abstract, e.g., discussion of the abstract done as part of a scientific presentation or presentation of additional or new information that will be available at the time of the meeting is embargoed from release to the general public until 8:00 am local time of the meeting location on the first day of the meeting.
Late-breaking abstracts will be available on the AASLD website and the online planner of The Liver Meeting® app on October 31 at 8:00 am ET and are published in the December issue of HEPATOLOGY. Information contained in those abstracts may not be released until the abstracts appear on the AASLD website.
Academic institutions, private organizations, and companies with products whose values may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an abstract on the AASLD website.
The purpose of the embargo policy is to protect the scientific integrity of the abstract submissions presented at The Liver Meeting®. Violation of the embargo policy by release of information contained in any abstract prior to its embargoed date and time may result in the individual, as well as the employer/affiliated company, institution, organization, etc., being removed from The Liver Meeting®, with a potential two-year ban on returning. Authors are responsible for notifying financial and other sponsors about this policy.
If the accepted abstract is also submitted as a manuscript for publication, authors are responsible for coordinating a publication date that abides by the AASLD Embargo Policy. If publication occurs online or in print before the specific embargo date and time set by AASLD, the abstract must be withdrawn.
On a case-by-case basis, AASLD may allow for exceptions to the Abstract Embargo Policy for publicly traded companies which must publicly disclose certain data from its submitted abstract prior to the embargo date in order to comply with the requirements of the U.S. Securities Exchange Commission (SEC) or a corresponding regulatory body in the country where the company’s stock is traded. However, AASLD requires the company President, General Counsel, or other appropriate official of a company seeking such an exception to attest in writing to the specific facts in support of the request, including exactly how the securities laws are implicated, with statutory citation(s). General statements of the need to comply with the law will not be considered sufficient. Requests for an exception must be sent to AASLD. AASLD requires a minimum of five (5) days from receipt of the request to evaluate the request. In granting an exception, AASLD may limit release of information to top-line data from the abstract and requires the company to state in their public disclosure that the complete and final results will be presented at The Liver Meeting®. AASLD will also require the inclusion of unreleased and unique data in such a presentation at The Liver Meeting®.
AASLD will evaluate exception requests on a case-by-case basis and reserves the right to change the type of presentation (from oral presentation to poster presentation) or remove the abstract from the meeting program if it determines that the released information may substantially detract from the novelty of the presentation.
Public release of a journal article relevant to the abstract will be considered an exception to the Embargo Policy if at the time of the abstract submission deadline, the decision concerning the manuscript had not been revealed to the authors. Authors are responsible to attempt to coordinate a publication date that abides by the AASLD’s Embargo Policy.
Questions regarding the embargo policy can be addressed to email@example.com